Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIMILAR
NCT06948097Phase 1Recruiting
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Nov 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in lung transplant rejection comparing Fostamatinib with Placebo (2 arms). Primary endpoints: Study Drug Discontinuation Rate at 12 weeks and Incidence of Adverse Events at 12 weeks. Started Nov 2026; status: recruiting.
02
Drugs
fostamatinib
03
Conditions
lung transplant rejection
Beyond the preview
Go deeper on NCT06948097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06948097.